Figure 6. Risk differences (RD) for RASBs treatment for patients with versus without cellular/fibrocellular crescents.

There were no significant differences in the use of RASBs between the two groups (RD, 0.09; 95% CI, -0.01-0.19; P = 0.071), with evidence of heterogeneity (I² = 69.0%; P = 0.040).